Histogenics Scientific Advisory Board
- Kyriacos A. Athanasiou, PhD, PE
Distinguished Professor and Chair Biomedical Engineering Department University of California Davis, USA
Prof. Athanasiou obtained his PhD from Columbia University in 1989 and has been a faculty member at the University of Texas and Rice University, prior to joining Davis in 2009. He has published 225 peer-reviewed papers, four authored books, and awarded 28 patents. He has also served as president of the Biomedical Engineering Society. He has received numerous honors, such as the Thomas Edison Award from ASME, the Presidential Award from BMES, the Marshall Urist Award from ORS, the Van C. Mow Medal from ASME, etc. He is currently the Editor-in-Chief of the Annals of Biomedical Engineering. In addition to his academic interests, he has co-founded numerous bioengineering companies, which have collectively brought to the market 15 FDA-approved products.
- Bruno Peault, Ph.D.
University of Edinburgh and Queen’s Medical Research Institute, University of California Los Angeles
Professor and Chair, Center for Cardiovascular Science at the University of Edinburgh and Queen’s Medical Research Institute; Professor, David Geffen School of Medicine and Orthopaedic Hospital Research Center at University of California at Los Angeles, whose research focuses on prospective identification, purification and functional characterization of multi-lineage stem cells present in human adult organs and tissues.
- R. Lane Smith, Ph.D.
Stanford University
Professor, Department of Orthopaedic Surgery at Stanford University, whose research focuses on understanding the fundamental biological and mechanical mechanisms influencing the differentiation, homeostasis and pathogenesis of bone, cartilage and dense connective tissues.
- Chia Soo, M.D.
University of California Los Angeles
Associate Professor, Department of Orthopaedic Surgery at University of California at Los Angeles, whose research focuses on bone and cartilage tissue engineering, stem cell-based approaches to regenerative medicine, and skin regeneration.
- Laurence Tarrant, Ph.D.
Founder and Chief Scientific Officer of Histogenics Corporation
Dr. Tarrant brings over thirty years of significant expertise in commercializing medical technologies and an innovator of three-dimensional scaffold technologies, the production of extracellular matrices and the use of hydrostatic pressure in the production of neocartilage tissue.
- Avner Yayon, M.D., Ph.D.
Founder and Chief Scientific Officer of ProChon Biotech, Ltd.
Dr. Yayon brings significant expertise in the modulation of fibroblast growth factor variants for therapeutic and cell expansion applications. Dr. Yayon’s research focuses on the molecular mechanisms underlying FGF-related genetic and acquired skeletal disorders and led to the development of the advanced cartilage regeneration implant, BioCart™II.